SPS
IRMD icon

Susquehanna Portfolio Strategies’s iRadimed IRMD Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$258K Sell
2,680
-674
-20% -$67.4K ﹤0.01% 866
2025
Q4 		$326K Buy
+3,354
New +$288K 0.01% 865

Other funds holding IRMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna Portfolio Strategies's IRMD Position: Q1 2026 in Review

Susquehanna Portfolio Strategies reduced its iRadimed (IRMD) stake by 20% in Q1 2026, selling an estimated $67.4K and leaving 2,680 shares worth $258K. The position accounts for ﹤0.01% of the portfolio, ranked #866.

Susquehanna Portfolio Strategies first reported a position in IRMD in Q4 2025 and has held it in 2 quarters since. The position peaked at $326K in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • Susquehanna Portfolio Strategies held 2,680 shares of iRadimed worth $258K as of Q1 2026.
  • Susquehanna Portfolio Strategies sold 674 iRadimed shares in Q1 2026, an estimated $67.4K.
  • iRadimed made up ﹤0.01% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #866 holding.
  • Susquehanna Portfolio Strategies first reported a position in iRadimed in Q4 2025 and has held it in 2 quarters since.
  • Susquehanna Portfolio Strategies's iRadimed position peaked at $326K in Q4 2025.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.